BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30910382)

  • 1. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation.
    Jiang G; Neuber B; Hückelhoven-Krauss A; Höpken UE; Ding Y; Sedloev D; Wang L; Reichman A; Eberhardt F; Wermke M; Rehm A; Müller-Tidow C; Schmitt A; Schmitt M
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manufacturing chimeric antigen receptor T cells: issues and challenges.
    Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
    Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cryopreservation on chimeric antigen receptor T cell functions.
    Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
    Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival
    Zhang A; Sun Y; Du J; Dong Y; Pang H; Ma L; Si S; Zhang Z; He M; Yue Y; Zhang X; Zhao W; Pi J; Chang M; Wang Q; Zhang Y
    Front Immunol; 2021; 12():724211. PubMed ID: 34675920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
    Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
    Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
    Front Immunol; 2020; 11():99. PubMed ID: 32117253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
    Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2021; 12():670088. PubMed ID: 34122428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
    Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
    Front Immunol; 2020; 11():1941. PubMed ID: 32849651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research Techniques Made Simple: CAR T-Cell Therapy.
    Siddiqi HF; Staser KW; Nambudiri VE
    J Invest Dermatol; 2018 Dec; 138(12):2501-2504.e1. PubMed ID: 30243656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.
    Leung WH; Gay J; Martin U; Garrett TE; Horton HM; Certo MT; Blazar BR; Morgan RA; Gregory PD; Jarjour J; Astrakhan A
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.